---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-26-000030"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:34:36.097670+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Curis Q4 net income $19.4M on Erivedge gain; PIPE raises $20.2M initial

## Summary
- FY2025 net loss $7.6M ($0.58/shr) vs $43.4M ($6.88/shr) in FY2024; Q4 net income $19.4M ($1.23/shr).
- Sold Erivedge royalty assets for $2.5M upfront and liability release; recognized $27.2M non-cash gain in Q4.
- Cash $5.1M at Dec 31; Jan 2026 PIPE raised $20.2M initial, up to $20.2M more from Series B warrants; runway into H2 2027.
- Initiated Phase 2 CLL study of emavusertib + zanubrutinib; PCNSL trial: 100% ORR in BTKi-naïve (5/5) patients.
- AML triplet study: 62.5% of patients (5/8) achieved MRD conversion to undetectable after adding emavusertib to aza-ven.

## SEC filing metadata
- accession: 0001108205-26-000030
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/0001108205-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/cris-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-26-000030
- JSON: https://secwatch.observer/filing/0001108205-26-000030.json
- Plain text: https://secwatch.observer/filing/0001108205-26-000030.txt

## Key facts
- Earnings Releases
  CURIS INC reported Fourth Quarter 2025 results: revenue $1.1 million, net income $19.4 million, EPS $1.23.
  - Period: Fourth Quarter 2025
  - Revenue: $1.1 million
  - Net income: $19.4 million
  - EPS: $1.23
  - Result: reported results
  source text: for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ® . Revenues were $1.1 million and $3.3 million for the fourth quarters of 2025 and 2024, respectively. As previously announced, on November 6, 2025, the Company sold to TPC Investments Royalty LLC, a limited
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/0001108205-26-000030-index.htm
- Earnings Releases
  CURIS INC reported Year ended December 31, 2025 results: revenue $9.4 million, net income $7.6 million, EPS $0.58.
  - Period: Year ended December 31, 2025
  - Revenue: $9.4 million
  - Net income: $7.6 million
  - EPS: $0.58
  - Result: reported results
  source text: per share on both a basic and diluted basis as compared to a net loss of $9.6 million or $1.25 on both a basic and diluted basis for the same period in 2024. Revenues, net were $9.4 million and $10.9 million for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/0001108205-26-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.